Twist Bioscience price to sales ratio TWST

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 20.3×
7-year median: 10.0×
Against its 7-year history: 73rd; percentile: 0 is its lowest day, 100 its highest
7-year range: 3.0× to 95.5×
Peer median: 7.3×

Twist Bioscience's price to sales ratio is 20.3× as of Oct 23, 2026.

That is above its 7-year median of 10.0×, higher than on 73% of days in the last 7 years.

Over that time it ranged from 3.0× in May 2023 to 95.5× in Jan 2021.

The median for 10 biotech stocks of a similar size is 7.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.3×	5.3×	27.4×
2025	5.4×	4.2×	10.3×
2024	9.1×	6.2×	12.2×
2023	8.7×	3.0×	8.7×
2022	6.6×	6.4×	25.0×
2021	29.0×	29.0×	95.5×
2020	70.8×	12.7×	82.2×
2019	13.4×	13.4×	16.1×

Against its peers

Companies in Biotechnology nearest Twist Bioscience's size, closest first, today.

Company	Price to sales ratio
TWSTTwist Bioscience	20.3×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
INCYIncyte	4.0×
UTHRUnited Therapeutics	8.0×
ALNYAlnylam Pharmaceuticals	6.2×
ADMAAdma Biologics	4.7×
Peer median	7.3×

Where Twist Bioscience ranks

#53of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Twist Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.